Product Image
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified version of GRF(1-29) conjugated with a Drug Affinity Complex (DAC) to extend its half-life. Extensively studied for growth hormone secretion and metabolic research applications.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It is a modified form of GRF(1-29) — the first 29 amino acids of GHRH — engineered with four amino acid substitutions to resist enzymatic degradation, and conjugated with a lysine-linked maleimidopropionic acid (MPA) group that binds to serum albumin, significantly extending its biological half-life. This modification allows for sustained elevation of growth hormone levels in research models, making it a valuable tool for studying the GH/IGF-1 axis and metabolic pathways.
| Molecular Weight | 3367.97 g/mol |
| Sequence | Modified GRF(1-29) with Drug Affinity Complex |
| Purity | ≥99% (HPLC) |
| Physical Form | Lyophilized powder |
| Storage | -20°C, keep away from light and moisture |
Disclaimer: This product is intended for laboratory and research use only. Not for human or animal consumption. All handling should be conducted by qualified researchers in accordance with applicable regulations.
Every batch of CJC-1295 sold by CertPeptides is independently tested by a third-party laboratory. The Certificate of Analysis (COA) confirms identity, purity (≥99% via HPLC), and the absence of heavy metals and microbial contamination.
A COA is included with every order. You may also request a batch-specific COA through our contact page.